Research
Hormonal
Bezafibrate treatment (400 mg/day) combined with lifestyle changes normalizes dysfunctional gene expression in NAFLD by decreasing synthesis genes (ACC1, FAS) and increasing oxidation genes (CPT1a, PPARα).
For NAFLD patients, a combination of bezafibrate (400 mg/day), a strict low-calorie diet, and exercise can normalize the expression of genes involved in fatty acid metabolism. This suggests that targeting PPARα with bezafibrate may be a beneficial treatment strategy.
ModerateSupportsMEDIUM confidence
We found that this treatment normalized dysfunctional expression of genes related to fatty acid metabolism, i.e. ACC1 and FAS expression were decreased and CTP1a and PPARα expression were increased.
Why this rating
Small subset (n=11) of the original cohort, data not shown in figures, but explicitly stated.
Source
Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease
Motoyuki Kohjima et al. · International Journal of Molecular Medicine · 2007
DOI 10.3892/ijmm.20.3.351
mechanism_only · n=36Cited 525×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In nonalcoholic fatty liver disease (NAFLD), hepatic de novo fatty acid synthesis and uptake are up-regulated (increased ACC1, FAS, SREBP-1c, ADRP) despite existing fatty acid accumulation, driven by a failure of negative feedback regulation.Good
- Mitochondrial fatty acid oxidation capacity in NAFLD is impaired or maximally activated, leading to compensatory up-regulation of peroxisomal and microsomal oxidation pathways.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →